FDA approves X4 Pharmaceuticals pill for ultrarare immunodeficiency disease Endpoints News

The first-ever RSV vaccines are inching closer to reality in what industry executives and analysts anticipate as the start of the next blockbuster vaccine race that could form a $10…

Johnson & Johnson’s Janssen scored an FDA approval with its licensed PARP inhibitor niraparib in combination with abiraterone acetate for the treatment of BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), the…

Though Christmas is right around the corner, the long biotech winter may soon be over. The Federal Reserve announced Wednesday it plans to cut interest rates three times next year,…